title: Technetium-99m hexamethylpropylene amine oxime lung scintigraphy findings in low-dose amiodarone therapy.
abstract: Amiodarone (AD)-induced pulmonary toxicity is one of the major complications of long-term AD therapy. Technetium-99m-labeled D: ,L: -hexamethylpropylene amine oxime (Tc-99m HMPAO) scintigraphy has been used to assess lung injury. We designed this study to clarify lung uptake changes of Tc-99m HMPAO using low doses of AD (5 mg/kg/day) during long-term therapy in a rabbit model. Group 1 consisted of 7 rabbits fed with AD by gavage for 6 months. To investigate the effect of ketamine on Tc-99m HMPAO uptake, 5 rabbits were included in Group 2 as a control group. Tc-99m HMPAO scintigraphy was performed in both Group 1 and Group 2 at baseline and after 2, 4, 6, 8, and 12 weeks of AD intake. After 16, 20, and 24 weeks of drug intake, Tc-99m HMPAO scintigraphy was repeated only in group 1. One-min anterior images were acquired 30 min after the injection of 37 MBq of Tc-99m HMPAO. For semiquantitative evaluation, the mean count values were obtained and lung/background and liver/background ratios were calculated. Histopathologic evaluation was performed. No increase in lung and liver uptake of Tc-99m HMPAO was found 2, 4, 6, 8, and 12 weeks after drug intake. There was no significant increase in L/B and H/B ratios of Tc-99m HMPAO in Group 1 compared with Group 2. Both scintigraphic studies and histopathologic examinations showed nonspecific changes. Longitudinal studies investigating Tc-99m HMPAO lung uptake may be planned in patients carrying risk factors for AD-induced lung toxicity.
authors.affiliation: Department of Nuclear Medicine, Dokuz Eylül University, School of Medicine, Izmir, Turkey. gamze.capa@deu.edu.tr
authors.forename: G Capa
authors.initials: GC
authors.lastname: Kaya
authors.forename: T
authors.initials: T
authors.lastname: Ertay
authors.forename: B
authors.initials: B
authors.lastname: Tuna
authors.forename: R
authors.initials: R
authors.lastname: Bekis
authors.forename: C
authors.initials: C
authors.lastname: Tasci
authors.forename: E
authors.initials: E
authors.lastname: Sayit
authors.forename: O
authors.initials: O
authors.lastname: Yilmaz
authors.forename: A
authors.initials: A
authors.lastname: Kargi
authors.forename: H
authors.initials: H
authors.lastname: Durak
mesh_terms: D000638:Amiodarone / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology; D008171:Lung Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging; D055370:Lung Injury; D008954:Models, Biological; D011817:Rabbits; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D019690:Technetium Tc 99m Exametazime / Q000493:pharmacokinetics
chemical_list: D000889:Anti-Arrhythmia Agents; D019275:Radiopharmaceuticals; D019690:Technetium Tc 99m Exametazime; D000638:Amiodarone